Follicular Lymphoma and Diffuse Large B-Cell Lymphoma — Proceedings from a Symposium Series Preceding the 67th ASH Annual Meeting and Exposition

Featuring perspectives from Dr Lindsey Roeker, including the following topics: Case: A man in his mid 60s with TP53-aberrant chronic lymphocytic leukemia (CLL) with extensive marrow infiltration receives first-line venetoclax/obinutuzumab and experiences an excellent response (0:00) Case: A man in his late 70s with small lymphocytic lymphoma (SLL) and cardiovascular comorbidities requiring verapamil and anticoagulation receives acalabrutinib/venetoclax; Case: A man in his early 80s with SLL receives zanubrutinib/sonrotoclax as part of the CELESTIAL-TNCLL trial (14:46) Case: A man in his late 70s with progressive CLL worsening after a skiing injury receives acalabrutinib/venetoclax as part of the MAJIC trial (22:37)

Featuring perspectives from Dr Lindsey Roeker, including the following topics: Consensus Approach to optimizing front-line treatment (0:00) Emerging role of sonrotoclax (8:39) Bruton tyrosine kinase inhibitor monotherapy for older patients; discontinuation (14:48) Evolving role of minimal residual disease assessment (19:16)

Featuring perspectives from Dr Spencer Bachow, Dr Bhavana (Tina) Bhatnagar, Dr Jennifer Crombie, Dr Manali Kamdar and Ms Alexandra Lynch, co-moderated by Dr Bachow and Dr Bhatnagar, including the following topics: Introduction and Overview of Bispecific Antibodies in the Clinic (0:00) Current and Future Role of Bispecific Antibodies in Non-Hodgkin Lymphoma — Dr Kamdar (15:58) Case: A man in his early 60s with diffuse large B-cell lymphoma (DLBCL) receives glofitamab (42:40) Case: A woman in her early 80s with follicular lymphoma (FL) receives mosunetuzumab (51:50) Mitigation and Management of Cytokine Release Syndrome (CRS) and Other Toxicities Associated with Bispecific Antibodies — Dr Crombie (1:00:39) Case: A woman in her early 80s with DLBCL receives glofitamab (1:18:50) Case: A woman in her early 70s with FL receives epcoritamab (1:26:38) Outpatient CRS Management in B-Cell Lymphomas — Ms Lynch (1:29:28) Case: A woman in her late 40s with FL receives epcoritamab (1:38:33) Case: A man in his early 70s with mantle cell lymphoma receives mosunetuzumab (1:46:26)

Featuring perspectives from Dr Catherine C Coombs, including the following topics: Phase III BRUIN CLL-322 trial of fixed-duration pirtobrutinib in combination with venetoclax and rituximab for previously treated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) (0:00) Role of allogeneic hematopoietic cell transplantation and chimeric antigen receptor T-cell therapy for relapsed/refractory (R/R) CLL (10:42) Fixed-duration venetoclax in combination with epcoritamab for R/R CLL/SLL; management of Richter’s transformation (15:50) Novel Bruton tyrosine kinase degraders bexobrutideg (NX-5948) and tacabrutideg (BGB-16673) (22:51)

Featuring perspectives from Dr Catherine C Coombs, including the following topics: Early versus delayed addition of obinutuzumab to acalabrutinib and venetoclax in treatment-naïve chronic lymphocytic leukemia (CLL) (0:00) Feasibility of discontinuation of Bruton tyrosine kinase (BTK) inhibitor therapy in CLL; minimal residual disease and disease monitoring (4:10) Ongoing Phase III trials of BTK inhibitor/B-cell lymphoma 2 inhibitor combinations in previously untreated CLL (10:05) Pirtobrutinib as first-line therapy for CLL and long-term safety data (15:22)